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Summary We examined the expression of basic fibroblast growth factor (FGF) and FGF receptor by
immunohistochemistry in 32 human pancreatic ductal adenocarcinomas. Mild to marked basic FGF
immunoreactivity was noted in 19 (59.4%) of the 32 tumours examined, and 30 (93.3%) of the tumours
exhibited a cytoplasmic staining pattern against FGF receptor. The tumours were divided into two groups
according to the proportion of positively stained tumour cells: a low expression group (positive cells<25%)
and a high expression group (positive cells k 25%). No statistically significant difference in tumour size,
differentiation, metastases or stage was found between the low and high basic FGF expression groups.
However, a significant correlation was found between FGF receptor expression level and the presence of
retroperitoneal invasion, lymph node metastasis, and tumour stage. In addition, low FGF receptor expression
was significantly associated with a longer post-operative survival as compared with high FGF receptor
expression, whereas there was no significant difference in post-operative survival between the low and high
basic FGF expression groups. Increased expression of FGF receptor is correlated with the extent of
malignancy and post-operative survival in human pancreatic ductal adenocarcinomas. Thus, overexpression of
FGF receptor may prove to be a more useful prognostic marker than basic FGF expression level in pancreatic
cancer patients.
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Members of the fibroblast growth factor (FGF, or heparin-
binding growth factor) family are potent mitogens for a wide
variety of mesodermal and neuroectodermal cells and have
been isolated from a variety of tissue and cell sources includ-
ing tumour cells (Thomas and Gimenetz-Gallego, 1986; Gos-
podarowicz et al., 1987). To date, at least nine members have
been identified from both normal and tumour tissues, includ-
ing basic FGF, acidic FGF, the int-2 gene product (FGF-3),
Kaposi FGF (FGF-4), FGF-5, FGF-6, keratinocyte growth
factor (FGF-7), androgen-induced growth factor, and FGF-9
(Klagsburn, 1989; Tanaka et al., 1992; Miyamoto et al.,
1993).
Basic FGF is thought to induce fibrosis, angiogenesis, and
tumour progression in human gastric carcinomas, renal cell
carcinomas, brain tumours, and malignant melanoma
through an autocrine mechanism (Becker et al., 1989;
Takahashi et al., 1990; Zagzag et al., 1990; Tanimoto et al.,
1991; Eguchi et al., 1992). Pancreatic carcinomas exhibit
strong stromal reactions, or desmoplasia, and have an
aggressive behaviour and poor prognosis (Ohta et al., 1993).
Therefore, it is feasible that basic FGF is the factor respon-
sible for desmoplasia and cancer cell proliferation in pan-
creatic carcinomas. This hypothesis is supported by a study
in which basic FGF expression was detected in two human
pancreatic carcinoma cell lines (Beauchamp et al., 1990). A
recent study (Yamanaka et al., 1993; Leung et al., 1994) has
also demonstrated the overexpression of basic FGF in
human pancreatic carcinoma tissues. In addition, pancreatic
carcinoma cells overexpress the FGF receptor which pos-
sesses intrinsic tyrosine kinase activity, raising the possibility
that the abundance of basic FGF and its receptor may
provide human pancreatic carcinoma cells with a con-
siderable growth advantage (Kobrin et al., 1993; Leung et al.,
1994). However, the tissue localisation of basic FGF and its
receptor proteins have not been fully elucidated in human
pancreatic carcinomas.
We examined the immunohistochemical localisation of
basic FGF and its receptor in human pancreatic carcinomas
and normal pancreatic tissues at the light and electron mic-
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roscopic level, and determined the relevance of this growth
factor system to malignant transformation and clinical
parameters including prognosis.
Materials and methods
Patients and tissue specimens
The present study included 32 pancreatic ductal adenocar-
cinomas surgically resected between 1987 and 1993. All
tumours were histologically proven to be pancreatic invasive
tubular and/or papillary adenocarcinoma. There were no
periampullary tumours or distal bile duct tumours not
originating from the pancreatic duct. The patients were 22
men and ten women, ranging from 32 to 77 years of age,
with a mean age of 63 years. Normal pancreatic tissues were
obtained from two male and three female patients undergo-
ing surgery for gastric cancer with combined resection of the
distal pancreas and spleen. The resected specimens with
attached peripancreatic lymph nodes and neural plexuses
were routinely fixed in 10% neutral-buffered formalin and
embedded in paraffin, and cut into 5 mm stepwise tissue
sections. Histological findings were evaluated according to
the General Rules for Cancer of the Pancreas proposed by
the Japanese Pancreatic Society (1986). All of the patients on
the study were followed until December 1993. Four patients
died within 60 days after surgery because of sepsis and
hepato-renal failure, and 22 patients relapsed with carcinoma
of the pancreas and died from progressive disease in the liver
and/or peritoneum. Two patients died of other or unknown
causes and four patients survived.
Three or more representative sections, including areas of
associated chronic pancreatitis adjacent to the carcinoma,
were used for immunohistochemical staining as described
below. In addition, in two selected cases, parallel samples
were fixed immediately with 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.2, for 4h. The tissue blocks were
further rinsed overnight in a phosphate buffer containing
20% sucrose, then cut into 15-20 tm sections on a cryostat
and mounted on poly-L-lysine-coated glass slides for
immunoelectron microscopy of basic FGF.b-FGF and its receptor in pancreatic cancer
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Antibodies
Monoclonal antibody against human basic FGF was
obtained and purified as described previously (Matsuzaki et
al., 1989; Yoshitake et al., 1991). This antibody is highly
specific for basic FGF from human, bovine and rodent
sources, and does not cross-react with acidic FGF. The
anti-FGF receptor antibody was a polyclonal antibody raised
in rabbits against purified human recombinant FGF receptor
(Flg-5) extracellular domain (Austral Biologicals, CA, USA).
This polyclonal antibody recognises recombinant human
FGF receptor as evidenced by Western analysis (Figure 1).
Light microscopic immunohistochemistry
Immunohistochemistry was performed using a three-step
indirect immunoperoxidase method (streptavidin-biotin-
peroxidase complex) as previously reported (Hughes and
Hall, 1993) with a slight modification. Briefly, 4tm sections
were mounted on poly-L-lysine-coated glass slides, air-dried,
and deparaffinised with graded xylene and alcohol. For basic
FGF staining, protease digestion was carried out using pro-
tease K (Boehringer Mannheim Biochemica, Germany) at a
concentration of 40 .Lm ml-' for 5 min at 37°C to facilitate
penetration of the primary antibody. Following a phosphate-
buffered saline (PBS) rinse, the sections were immersed in
absolute methanol containing 0.3% hydrogen peroxide to
block endogenous peroxidase activity, and incubated with
normal goat serum at a 1:30 dilution for 30 min at room
temperature to block non-specific binding. Each primary
antibody was diluted in PBS/0.3% bovine serum albumin
and used at the predetermined optimal dilution (10 fgml-').
After overnight incubation at 4°C, the sections were rinsed in
PBS and incubated for 1 h at room temperature with a
biotinylated goat anti-mouse or goat anti-rabbit IgG
kDa
200
(Dakopatts, Copenhagen, Denmark). The pcroxidase labelled
streptavidin (Dakopatts, Copenhagen, Denmark) was then
added for 30 min at room temperature. Reaction products
were developed by immersing the sections in a 3.3'-
diaminobenzidine tetrahydrochloride solution containing
0.1% hydrogen peroxide. Slides were counterstained lightly
with methyl green. In each immunostaining run, the primary
antibody was replaced by non-immune normal mouse serum
(Dako, Santa Barbara, CA, USA) or PBS as negative cont-
rols, which resulted in no detectable staining. Sections from
normal skin tissue specimens were used as positive controls
which showed positive staining of sweat and sebaceous
glands (Hughes and Hall, 1993).
Immunohistochemical quantification ofstaining with basic FGF
or FGFreceptor
The degree of primary antibody reactivity on individual tis-
sue sections was scored semi-quantitatively (percentage of
stained carcinoma cells in the section) by two authors (TO
and YT) without knowledge of the patients' outcome or
clinicopathological features. Tumours with more than 5%
stained cells were defined as positive and all others as
negative. The proportion of positively stained tumour cells
was subdivided as follows: minimal (+) denotes 5-25% of
cells positive, moderate (+ +) denotes 25-50% of cells
positive, and marked (+ + +) denotes more than 50% of
cells positive. In addition, staining intensity was evaluated
visually and each specimen was assigned to one ofthe follow-
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Figure 1 Western blot analysis of the specificity of anti-FGF
receptor polyclonal antibody. The recombinant human FGF
receptor (Austral Biologicals, CA, USA) conjugated with BSA
(0.1 tLg per lane) was electrophoresed, blotted onto a nitrocel-
lulose membrane, and immunoreacted with anti-FGF receptor
antibody (a) and non-immune normal rabbit serum (b) at 1:200
dilution in PBS. As a result, the anti-FGF receptor antibody
immunoreacted with recombinant human FGF receptor con-
jugated with BSA, forming a single major band of approximately
68 kDa. In contrast, non-immune normal rabbit serum showed
no reaction with this antigen.
2 3 .. - ; ! 6 F k ' i
Figure 2 Light microscopic immunostaining for basic FGF and
FGF receptor in normal human pancreas. (a) Basic FGF
immunoreactivity is present in a heterogenous pattern in acinar
cells, and is rarely present in ductal cells (x 140); (b) FGF
receptor is present in ductal cells and centroacinar cells, however,
there is no staining in the acinar cells. Endothelial cells in the
stroma (arrows) occasionally show FGF receptor immunoreac-
tivity (x 140).
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ing categories: no staining (-), weak staining (W), and
strong staining (S).
To determine the relationship between the overexpression
of basic FGF or the FGF receptor and the biological
behaviour of invasive ductal adenocarcinoma of the pan-
creas, the 32 patients were classified into two groups accord-
ing to the proportion of positively stained tumour cells:
group 1, patients with no staining or with less than 25%
positive tumour cells (low-expression group); group 2,
patients with more than 25% positive tumour cells (high-
expression group).
Electron microscopic immunocytochemistry
Sections immunostained using the three-step indirect
immunoperoxidase method described above were post-fixed
with 0.5% osmium tetroxide for 20 min at room temperature.
After block-staining with uranyl acetate, the sections were
dehydrated in graded ethanol, embedded in Epon 812, and
cut into ultrathin sections.
Statistical analysis
Statistical comparisons on baseline data between the two
groups were performed by the chi-square test. The cumu-
lative survival rate was calculated by the Kaplan-Meier
method. This was done under the consideration that the
number of cases in each group was not large. Statistical
analysis of differences between the two groups was made by
the log-rank test. The difference was considered to be
significant when P<0.05.
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Results
Light microscopic immunohistochemistryfor basic FGF
In most sections of normal pancreas, moderate basic FGF
immunoreactivity was present in a heterogeneous pattern in
acinar cells. It was most important at the basal aspect of the
acinar cells (Figure 2a). Relatively weak cytoplasmic staining
of some intralobular and interlobular duct cells was also
seen. However, immunostaining was rarely present in islet
cells or stromal cells.
Nineteen of the 32 pancreatic ductal adenocarcinomas
(59.4%) showed minimal to marked immunoreactivity for
basic FGF (Table I). Eleven of the 19 positively stained
tumours exhibited cytoplasmic immunoreactivity (Figure
3a,b), while the other eight showed predominantly nuclear
immunoreactivity, a phenomenon which was not observed in
the normal pancreas (Figure 3c). Twelve of the adenocar-
cinomas (40.6%) showed little or no immunostaining in the
carcinoma cells. However, intense basic FGF immunoreac-
tivity was seen in many surrounding stromal cells including
fibroblasts and macrophages (Figure 3d). In areas of
associated chronic pancreatitis, there was a considerable in-
crease in basic FGF immunoreactivity in the atrophied
acinar and ductal cells in comparison with normal pancreas.
Light microscopic immunohistochemistryfor FGFreceptor
Most sections of normal pancreas showed intense cytoplas-
mic staining for FGF receptor in intralobular, interlobular
b
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Figure 3 Light microscopic immunostaining for basic FGF in human pancreatic ductal adenocarcinoma. (a) and (b) Intense
cytoplasmic immunoreactivity for basic FGF is present not only in carcinoma cells but also in the surrounding fibroblasts (x 70
and x 210 respectively). Endothelial cells in the stroma (arrow) also react with basic FGF; (c) Some tumours exhibit a
predominant nuclear immunoreactivity (x 140); (d) There is no staining in carcinoma cells. However, the surrounding stromal cells,
including fibroblasts and macrophages, show intense basic FGF immunoreactivity (x 112).b-FGF and its receptor in pancreatic cancer I
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Table I Immunostaining ofhuman pancreatic cancer specimens with
anti-basic FGF and anti-FGF receptor antibodies
Basic FGF FGF receptor
Case Stained Staining Staining Stained Staining
Number proportion intensity pattern proportion intensity
1 +++ W N +++ S
2 ++ W C ++ S
3 ++ S C ++ S
4 +++ S N +++ S
5 ++ W C +++ S
6 ++ W C +++ S
7 +++ S N ++ S
8 +++ S N ++ S
9 +++ S N +++ S
10 ++ W C +++ S
11 ++ w C +++ S
12 +++ W C +++ S
13 ++ W C +++ S
14 ++ S N + S
15 ++ w C +. S
16 ++ S N + S
17 ++ S N + S
18 + W C +++ S
19 + W C ++ S
20 - - ++ S
21 - - +++ S
22 - - +++ S
23 - - ++ S
24 - - ++ S
25 - - ++ S
26 - - ++ S
27 - - ++ S
28 - - +++ S
29 - - ++ S
30 - - + S
31 - -
32 _
Stainedproportion:-, allcellsnegativeor <5% ofcellspositive; +,
5-20% of cells positive; + +, 25-50% of cells positive; + ++,
50-100% ofcells positive. Staining intensity: -, no staining; W, weak
intensity; S, strong intensity. Stainingpattern: N, nuclear staining type;
C, cytoplasmic staining type.
and main pancreatic duct cells and weak cytoplasmic staining
ofcentroacinar cells and intercalated ducts (Figure 2b). How-
ever, there was no staining in the acinar cells, islet cells or
surrounding stromal cells.
Thirty of the 32 pancreatic ductal adenocarcinomas
(93.8%) showed minimal to marked immunoreactivity for
FGF receptor (Table I). The staining intensity in the tumours
varied from specimen to specimen, as well as from area to
area within the same specimen. In these positive cells, FGF
receptor was found on both the cell surface and in the
cytoplasm, and was especially prominent at the apical sur-
faces (Figure 4). There was no or only weak immunostaining
in the stromal cells surrounding the carcinoma cells. How-
ever, in some cases, stromal cells in the infiltrative margin of
the tumours showed moderate to strong immunoreactivity. In
the area of associated chronic pancreatitis, there was a con-
siderable increase in FGF receptor immunoreactivity in the
atrophied acinar and ductal cells in comparison with a nor-
mal pancreas.
Immunoelectron microscopyfor basic FGF
Most spindle-shaped cells positive for basic FGF were
identified as fibroblasts (Figure 5a). The immunoreactivity
for basic FGF was located in the cytosol (cytoplasmic mat-
rix), and was especially prominent in the cytosol adjacent to
the rough endoplasmic reticulum. Carcinoma cells also
showed basic FGF immunoreactivity in the cytosol and
rarely in the rough endoplasmic reticulum and Golgi
apparatus (Figure Sb). No distinct staining was detected in
the nucleus in the two specimens examined.
b
Figure 4 Light microscopic immunostaining for FGF receptor in
human pancreatic ductal adenocarcinomas. FGF receptor is
found on both the cell surface and in the cytoplasm, and is
especially prominent at the apical surfaces of carcinoma cells (a,
x 70; b, x 182).
Relationship between basic FGF or FGFreceptor expression
levels andclinicopathologicalfeatures inpancreatic cancers
No statistically significant difference in tumour size, tumour
location, anterior capsular invasion, retroperitoneal invasion,
histological differentiation, presence of lymph node meta-
stases, presence of liver metastases, or tumour stage were
found between the low and high basic FGF expression
groups (Table II). In contrast, significant difference in
retroperitoneal invasion (P<0.05), lymph node metastasis
(P<0.05), and tumour stage (P<0.01) was found between
the low and high FGF receptor groups (Table II).
Survival analysis
Survival data were available for 28 of the 32 patients. There
was no significant difference in post-operative survival
between the low and high basic FGF expression groups
(Figure 6). In contrast, low FGF receptor expression was
associated with longer post-operative survival as compared
with high FGF receptor expression and this difference was
statistically significant (P<0.01), although the low FGF
receptor expression group represented only a small subgroup
of the total population (Figure 7).
Discussion
The detection of small pancreatic cancers in Japan has been
increasing with improvements in diagnostic methods and theb-FGF and its receptor in pancreatic cancer
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Figure 5 Immunoelectron micrograph for basic FGF in human
pancreatic ductal adenocarcinoma. (a) Immunoreactivity in a
fibroblast adjacent to carcinoma cells is mainly located in the
cytosol adjacent to the rough endoplasmic reticulum (x 8800); (b)
Carcinoma cell with intense immunoreactivity in the cytosol, and
rarely in the rough endoplasmic reticulum and Golgi apparatus
(x 16000).
discovery of tumour markers for pancreatic cancer (Ariyama
et al., 1990; Satake et al., 1991). However, even if pancreatic
ductal adenocarcinomas, excluding an intraductal variant of
mucin-producing pancreatic tumour (Morohoshi et al., 1989),
are detected early and completely resected, the incidence of
recurrence after pancreatectomy is high and the prognosis is
poor (Kayahara et al., 1993; Ohta et al., 1993). This may be
due to the aggressive biological behaviour of this cancer.
Recently, various prognostic factors for pancreatic cancers,
including DNA nuclear content analysis, argyrophilic
nucleolar organiser region (Ag-NOR) counts, and the
presence or absence of overexpression of various proto-
oncogenes, growth factors, and their receptors have been
investigated. However, there have been only a few reports of
reliable prognostic factors for pancreatic cancers (Alanen et
al., 1990; Motojima et al., 1991; Tian et al., 1992; Nakamori
et al., 1993). Therefore, it is essential to examine resected
specimens for features that might correlate with survival.
These features, if identified, would be a guide to prognosis
after operation.
Basic FGF has been implicated in tumour angiogenesis
through its ability to stimulate the growth of endothelial cells
(Folkman and Klagsburn, 1987). Additionally, this growth
factor stimulates fibroblast and epithelial cell growth (Riz-
zino et al., 1986; Ristow and Messmer, 1988). Basic FGF
mediates its biological effects by binding to a high-affinity cell
surface receptor (FGF receptor) containing an intracellular
tyrosine kinase domain (Fresel et al., 1986; Olwin and
Hauschka, 1989; Klagsburn and Baird, 1991). Schweigerer et
al. (1987b) reported that basic FGF is an autocrine growth
factor for human embryonal rhabdomyosarcoma cells. In
addition, human gastric cancers, gliomas, meningiomas and
renal cell carcinomas have been reported to express basic
FGF mRNA (Takahashi et al., 1990; Zagzag et al., 1990;
Tanimoto et al., 1991; Eguchi et al., 1992), and Kaposi's
sarcoma cells have been reported to release basic FGF into
their medium (Ensoli et al., 1989). However, basic FGF lacks
a typical signal peptide region which facilitates secretion
(Gospodarowicz et al., 1987) and its release mechanism re-
mains unknown. Cell lysis or leakage may be involved in the
release of basic FGF as the existence of similar mechanisms
has been proposed for interleukin-1, another growth factor
that lacks a signal peptide (Auron et al., 1984; March et al.,
1985; Schweigerer et al., 1987a; Lemoine et al., 1993).
Previous studies have demonstrated that human pancreatic
carcinoma cell lines overexpress basic FGF and the FGF
receptor (Beauchamp et al., 1990; Lemoine et al., 1993). In
addition, a recent study has indicated that there are increased
levels of basic FGF and FGF receptor in human pancreatic
cancers as compared with normal human pancreatic tissues,
using immunohistochemical staining, northern blotting, and
in situ hybridisation (Kobrin et al., 1993; Yamanaka et al.,
1993; Leung et al., 1994). In the present study, we demon-
strated the presence of basic FGF and FGF receptor expres-
sion in human pancreatic cancers and normal pancreatic
tissues by immunocyto- and immunohistochemistry. In the
normal pancreas, moderate to marked basic FGF immuno-
reactivity was present in a heterogeneous pattern at the basal
aspect of acinar cells, and intense cytoplasmic FGF receptor
immunoreactivity was seen in intralobular, interlobular and
main pancreatic duct cells. Additionally, in the human pan-
creatic cancers minimal to marked basic FGF immunoreac-
tivity was noted in 19 (59.4%) of the 32 tumours and 30
(93.8%) tumours showed minimal to marked cytoplasmic
staining for FGF receptor. This suggests that there is con-
comitant expression of basic FGF and FGF receptor in
pancreatic ductal adenocarcinomas, which may allow for
excessive autocrine growth stimulation. Furthermore, eight
(25%) tumours had nuclear staining for basic FGF, support-
ing the concept of an intracellular stimulating effect like that
of sis protein (Yamamoto et al., 1991; Nakanishi et al.,
1992), i.e. the presence of basic FGF protein in the nucleus
has raised the possibility of specific nuclear functions for this
molecule in addition to signalling at the cell surface (Mason,
1994). Thus, tumour-derived basic FGF may play a role as ab-FGF and Itsreceptor inpanreaticcancer
TOhta etal PA
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TableII RelationshipbetweenbasicFGForFGFreceptorexpressionlevelandclinicopathologicalfeatures
in human pancreatic cancers
Basic FGF FGFreceptor
Low expression High expression Low expression High expression
Variablesa group (%) group (%) group (%) group (%)
No. ofpatients 15 17 7 25
Tumour size
K3.0 cm 3 (20) 4 (24) 3 (43) 4 (16)
>3.0cm 12(80) 13(76) 4(57) 21 (84)
Tumour location
Head 13 (87) 11 (65) 4 (57) 19 (76)
Body and tail 2 (13) 6 (35) 3 (43) 6 (24)
Anterior capsular invasion
Negative 8 (53) 7 (41) 4 (57) 11 (44)
Positive 7 (47) 10 (59) 3 (43) 14 (56)
Retroperitoneal invasion
Negative 3 (20) 3 (18) 4 (57) 2 (8)
Positive 12 (80) 14 (82) 3 (43)b 23 (92)b
Histological differentiation
Well/moderately 14 (93) 15 (88) 7 (100) 22 (88)
Poorly 1 (7) 2 (12) 0 3 (12)
Lymph node metastasis
Negative 3 (20) 1 (6) 3 (43) 1 (4)
Positive 12 (80) 16 (94) 4 (57)b 24 (96)b
Liver metastasis
Negative 12 (80) 13 (76) 6 (86) 19 (76)
Positive 3 (20) 4 (24) 1 (14) 6 (24)
Tumour stage
I/II 2 (13) 2 (12) 4 (57) 0
III/IV 13 (87) 15 (88) 3 (43)b 25 (1OO)b
aHistological findings areevaluated according to theGeneralRulesforCancerofthe Pancreasproposed by
the Japanese Pancreatic Society (1986). "Analysed by chi-square test. P<0.05.
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Figure 6 Cumulative survival curves of patients with resected
pancreatic ductal adenocarcinomas, subdivided according to the
basic FGF expression level. 0-0, High-expression group
(positive cells > 25%); *-*, low-expression group (positive
cells <25%). There is no significant difference in post-operative
survival between the low and high basic FGF expression groups.
potent mitogen in tumour growth and desmoplastic response;
however, the main function of this protein in human pan-
creatic ductal cancers may not be to promote angiogenesis
because pancreatic ductal cancers are almost invariably
hypovascular. In contrast, brain tumours are known to have
more intense neovascularisation than other tumours and pro-
duce basic FGF as a potent angiogenic mediator (Li et al.,
1994). Additionally, although 13 tumours (40.6%) showed no
basic FGF immunoreactivity, intense basic FGF immuno-
reactivity was seen in the adjacent fibroblasts in all basic
FGF negative tumours, and 11 of 13 basic FGF negative
tumours (84.6%) displayed mild to marked immunoreactivity
to the FGF receptor. These findings suggest that basic FGF-
negative carcinoma cells could be targets for paracrine
growth control by basic FGF produced by stromal com-
ponents. This hypothesis is supported by several experimental
24 36 4
Follow-up (months)
Figure 7 Cumulative survival curves of patients with resected
pancreatic ductal adenocarcinomas, subdivided according to the
FGF receptor expression level. 0-0, High-expression group
(positive cells > 25%); *-*, low-expression group (positive
cells <25%). Low FGF receptor expression is significantly
associated with longer post-operative survival (P<0.01).
studies suggesting the importance of contacts between
tumour cells and fibroblasts (Tanaka et al., 1988; Coucke et
al., 1992; Gartner et al., 1992).
In the present study, high levels of FGF receptor expres-
sion was associated with the presence of retroperitoneal
invasion and lymph node metastasis, and with advancing
tumour stage, although no statistically significant difference
in variable clinicopathological factors was found between the
low and high basic FGF expression groups. In addition, low
FGF receptor expression was significantly associated with
longer post-operative survival, whereas there was no
significant difference in post-operative survival between the
low and high basic FGF expression groups. Thus, overex-
pression of FGF receptor may prove to be a more useful
prognostic marker than basic FGF expression in pancreatic
cancer patients. However, a recent study (Yamanaka et al.,b-FGF and its receptor in pancreatic cancer
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1993) has shown that overexpression of basic FGF is
associated with poor prognosis, although almost all the
patients had a poor prognosis and died within 3 years of
surgery. Further studies with a large number of patients,
including a multivariate analysis, are needed to determine
whether expression of basic FGF or of the FGF receptor is a
better prognostic marker for patients with completely
resected adenocarcinoma of the pancreas.
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